Health Equity & Access Weekly Roundup: March 27, 2026

CDC Opioid Guidelines at 10: Impact, Misuse, and Lessons: Michael Lynch, MD

In an interview reflecting on the decade since the CDC first issued its opioid prescribing guidelines, Michael Lynch, MD, FACMT, an associate professor of emergency medicine at the University of Pittsburgh School of Medicine, said their impact on overdose trends is difficult to isolate, given the simultaneous rise of illicit fentanyl, now the primary driver of overdose deaths. While prescription opioid–related deaths have plateaued or declined, Lynch emphasized that the guidelines were often misapplied as rigid rules rather than flexible recommendations, leading to unintended consequences such as rapid tapering and reduced access for patients with chronic pain. He stressed the need for more individualized, patient-centered approaches to pain management, noting improvements in avoiding high-dose prescribing but warning that overly prescriptive policies can cause harm. Looking ahead, he called for future frameworks to balance safety with patient needs, anticipate unintended consequences, and maintain flexibility to reflect the complexity of pain care.

IRA Drug Provisions Linked to Significant Drop in Medicare Medication Nonadherence

Two new studies provide early, rigorous evidence that the 2024 prescription drug reforms under the Inflation Reduction Act (IRA) are improving medication adherence among Medicare beneficiaries, particularly those with chronic conditions and lower incomes. Key provisions—eliminating the 5% coinsurance in catastrophic coverage and expanding eligibility for full low-income subsidies—reduced cost-related nonadherence by nearly 5 percentage points overall and up to 7.8 points among patients with multiple conditions, with similar gains seen in cardiovascular populations newly eligible for subsidies. However, the removal of catastrophic coinsurance alone had limited impact, suggesting income-based subsidies are more effective in the short term. While these changes have not yet reduced broader financial strain, they signal meaningful progress, with additional IRA measures, such as a $2000 out-of-pocket cap and future drug price negotiations, expected to further improve affordability and adherence, though plan design changes could offset some benefits.

From Trials to Pathways: Rethinking Access in Oncology Care

At the February 2026 Boston Regional Institute for Value-Based Medicine^® event, oncology experts highlighted how improving clinical trial diversity, expanding medically integrated dispensing (MID), refining treatment pathways, and strengthening academic-community partnerships are critical to advancing equitable, value-based cancer care. Panelists emphasized persistent barriers to trial access—including transportation, awareness, and underrepresentation of certain populations—and the growing role of patient navigators and more flexible trial designs in addressing these gaps. MID models were noted for improving medication access, affordability, and care coordination through on-site pharmacy services and real-time data sharing. Meanwhile, discussions on oncology pathways stressed prioritizing safety and efficacy over cost, and collaboration between academic and community settings was identified as essential for translating innovation into broader, practical patient care.

In New York, Experts Navigate the Dichotomy of Uncertainty Amid Innovation in Cancer Care

At a February 2026 Institute for Value-Based Medicine meeting in New York, oncology experts highlighted both progress and ongoing challenges shaping cancer care, from advances in targeted therapies and biomarker testing to persistent gaps in clinical trial diversity and affordability. Panelists emphasized the importance of comprehensive up-front genomic testing, particularly using next-generation sequencing, to guide increasingly personalized lung cancer treatments, while also noting logistical, insurance, and workflow barriers. Discussions also underscored continued disparities in trial enrollment driven by socioeconomic factors, mistrust, and access issues, alongside calls for more inclusive, flexible study designs. Broader conversations on value-based care stressed balancing outcomes with costs, improving transparency, and leveraging collaboration across institutions. Finally, medically integrated pharmacies were highlighted as a key innovation, improving medication access, coordination, adherence, and cost efficiency through real-time care integration and streamlined delivery.

Policy Measures Lower Out-of-Pocket Insulin Costs for Medicare Part D Beneficiaries

A new study found that insulin affordability for Medicare Part D beneficiaries without low-income subsidies improved significantly from 2019 to 2023 due to policy changes including the CMS Senior Savings Model and the IRA. The share of patients paying $35 or less for a 30-day insulin supply rose from 48% to 75%, while average out-of-pocket costs dropped by nearly 56%, from about $51 to $22. However, about one-quarter of beneficiaries still paid more than $35, largely due to nonstandard prescription quantities that were not prorated to the monthly cap. Although costs declined across all states, geographic variation persisted, and researchers noted that further aligning pricing with the $35 cap could enhance affordability even more.